{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:55:06Z","timestamp":1787853306552,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cllc.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T17:23:07Z","timestamp":1723569787000},"page":"634-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced\/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons"],"prefix":"10.1016","volume":"25","author":[{"given":"Christine","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Abrahami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Mark","family":"Kelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Thomaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2024.08.003_bib0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Nat Comp Cancer Net"},{"key":"10.1016\/j.cllc.2024.08.003_bib0002","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.08.003_bib0004","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0005","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cllc.2022.07.008","article-title":"Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic alk\u2013inhibitor-naive alk+ non\u2013small cell lung cancer: final results from the phase III ALTA-1L study","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.08.003_bib0006","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2024.08.003_bib0007","doi-asserted-by":"crossref","first-page":"S1563","DOI":"10.1016\/j.annonc.2022.10.353","article-title":"LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-na\u00efve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study","volume":"33","author":"Zhou","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0008","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.08.003_bib0009","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.cllc.2024.08.003_bib0010","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.3390\/cancers13153704","article-title":"Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis","volume":"13","author":"Ando","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cllc.2024.08.003_bib0011","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3390\/cancers13081966","article-title":"Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-na\u00efve ALK-positive lung cancer","volume":"13","author":"Chuang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cllc.2024.08.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-060782","article-title":"ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis","volume":"12","author":"Jiang","year":"2022","journal-title":"BMJ open"},{"key":"10.1016\/j.cllc.2024.08.003_bib0013","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40258-023-00807-7","article-title":"Cost\u2011Effectiveness of lorlatinib in first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)\u2011positive non\u2011small\u2011cell lung cancer in Sweden","volume":"21","author":"Naik","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.cllc.2024.08.003_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754768","article-title":"Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a Bayesian network meta-analysis","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0015","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.08.003_bib0016","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2217\/fon-2022-0194","article-title":"Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer","volume":"18","author":"Reckamp","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0017","unstructured":"Phillippo D, Ades T, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE2016. https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed March 1, 2023."},{"key":"10.1016\/j.cllc.2024.08.003_bib0018","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cllc.2024.08.003_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.cllc.2024.08.003_bib0020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.cllc.2024.08.003_bib0022","unstructured":"National Institute for health and Care Excellence (NICE). Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not beenpreviously treated with an ALK inhibitor: technology appraisal guidance [TA670]2021. https:\/\/www.nice.org.uk\/guidance\/ta670. Accessed March 1, 2023."},{"key":"10.1016\/j.cllc.2024.08.003_bib0023","unstructured":"National Institute for Health and Care Excellence (NICE). Alectinib for untreated ALK-positive advanced non-small-cell lung cancer: technology appraisal guidance [TA536] 2018. https:\/\/www.nice.org.uk\/guidance\/ta536. Accessed March, 1 2023."},{"key":"10.1016\/j.cllc.2024.08.003_bib0024","unstructured":"National Institute for Health and Care Excellence (NICE). Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer: Technology Appraisal Guidance [TA909]2023. https:\/\/www.nice.org.uk\/guidance\/ta909\/resources\/lorlatinib-for-untreated-alkpositive-advanced-nonsmallcell-lung-cancer-pdf-82615435069381. Accessed August 15, 2023."},{"key":"10.1016\/j.cllc.2024.08.003_bib0032","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Resp Med"},{"key":"10.1016\/j.cllc.2024.08.003_bib0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0026","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/jrsm.1511","article-title":"Methods for population adjustment with limited access to individual patient data: a review and simulation study","volume":"12","author":"Remiro-Az\u00f3car","year":"2021","journal-title":"Research synthesis methods"},{"key":"10.1016\/j.cllc.2024.08.003_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jval.2018.06.018","article-title":"Alternative weighting approaches for anchored matching-adjusted indirect comparisons via a common comparator","volume":"22","author":"Petto","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.cllc.2024.08.003_bib0028","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1111\/cas.15777","article-title":"Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer","volume":"114","author":"Goto","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2024.08.003_bib0029","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11523-023-00973-7","article-title":"ALK inhibitor treatment patterns and outcomes in real-world patients with ALK-positive non-small-cell lung cancer: a retrospective cohort study","volume":"18","author":"Wang","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non\u2013small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.08.003_bib0033","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/jpm.2006.0202","article-title":"Quality of life in patients with brain metastases treated with a palliative course of whole-brain radiotherapy","volume":"10","author":"Doyle","year":"2007","journal-title":"J Palliat Med"},{"key":"10.1016\/j.cllc.2024.08.003_bib0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.21037\/apm.2016.04.01","article-title":"Quality of life with brain symptom and impact questionnaire in patients with brain metastases","volume":"5","author":"Chow","year":"2016","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.cllc.2024.08.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042400158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042400158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:48:57Z","timestamp":1729871337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042400158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S152573042400158X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.08.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced\/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}